Journal of Traditional Chinese Medicine · Oct 2026

Bushen Huoxue decoction attenuates osteoporosis in ovariectomized rats through suppressing osteoclast differentiation by targeting sirtuin 1 to deactivate nuclear factor-κB

By Shuai C, Jie J, Yuwen HU et al.

OBJECTIVE: To investigate the anti-osteoporotic effects of Bushen Huoxue decoction (, BSHXD) and its underlying molecular mechanisms in a postmenopausal osteoporosis (PMOP) model. METHODS: The model of PMOP was established by bilateral ovariectomy in female rats, and each group were given different doses of BSHXD, or Alendronate by oral gavage. Then, the therapeutic effect of BSHXD on PMOP was estimated using micro-CT analysis, histological staining, and immunohistochemical analysis. In vitro experiment, immunofluorescence analysis, luciferase assay, and co-immunoprecipitation (Co-IP) were used to examine the potential impact and mechanism of BSHXD on osteoclast differentiation. Additionally, Sirtinol was employed to silence Sirt1 and further investigate its involvement in the protective effects of BSHXD. RESULTS: Our study demonstrated that BSHXD ameliorates bone loss and improves trabecular microstructure in osteoporosis model rats. Simultaneously, histological analysis revealed that BSHXD treatment led to a downregulation of tartrate-resistant acid phosphatase (Trap), matrix metalloproteinase 9, and nuclear factor of activated T cells cytoplasmic 1 expression. In addition, the in vitro experiment provided evidence that BSHXD effectively inhibits the formation of osteoclasts and reduces Trap positive osteoclasts. Luciferase assay and CO-IP analysis revealed that BSHXD decreases the acetylation level of nuclear factor NF-kappa-B p65 subunit (p65) and suppresses the activity of nuclear factor-κB (NF-κB), and significantly promotes the binding of Sirtuin 1 (Sirt1) to p65. Notably, after administration with the Sirt1 inhibitor, the antiosteoporotic effect of BSHXD was reduced and NF-κB activity was increased. CONCLUSION: BSHXD promoted p65 deacetylation by activating Sirt1, thereby inhibiting the NF-κB pathway and subsequently alleviating osteoclast differentiation and bone resorption.

doi.org/10.19852/j.cnki.jtcm.2026.05.007Open accessPubMed 42958664Interventions

AgingResearch.News